Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 333Observational 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Infections 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Blood Specimen Collection 135Surveys and Questionnaires 132Specimen Handling 57Observation 55Radiotherapy 43Interviews as Topic 35Surgical Procedures, Operative 31Biopsy 30Drug Therapy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Immune Checkpoint Inhibitors 18Watchful Waiting 18Standard of Care 17Therapeutics 17Immunotherapy 16Magnetic Resonance Imaging 16trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13palbociclib 13Radiosurgery 12enzalutamide 12Focus Groups 11Hematologic Tests 11apalutamide 11darolutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Rituximab × 1 year × Clear all
NCT06790420 2026-05-15

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Pfizer

Completed
2,703 enrolled 13 charts
Lymphoid

Infections, Lymphoma

NCT07200583 2025-11-18

PAIA-Haplo

Fujian Medical University

Completed
50 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

NCT07233720 2025-11-18

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Recruiting
30 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡